Influence of Combination Therapy of Oral Anti Diabetics on HbA1c Values

Type 2 diabetes mellitus has been one of the most common chronic, metabolic diseases whose prevalence is steadily increasing worldwide. The choice of therapy (either mono or dual therapy) or the choice of agent is based on the blood glucose levels and patient characteristics. When metformin alone is insufficient to achieve the glycemic target, adding basal insulin or a sulfonylurea is recommended as a well - validated therapy strategy, whilst pioglitazone or glucagon - like peptide - 1 (GLP - 1) agonists are suggested as less well - validated combination therapies. If a patient is on dual therapy and the HbA1c value remained above 7.5%, it is recommended to have a third - line treatment with a glitazone or insulin. An observational study was carried out for a period of three months to estimate the influence of oral hypoglycemic agents in combination therapy in improving the hba1c levels. After eliminating all the individuals who do not met the criteria, the observation was carried out in 257 individuals and their hba1c values were collected during follow - up. The mean values of hba1c are calculated for each category of hypoglycemic agent and the effective agent that can actually improve the hba1c value is estimated.